Colorectal Cancer Screening and Surveillance

  • Susan K. Clark


Worldwide, colorectal cancer causes approximately 600,000 deaths per year [1]. About 16,000 of these occur in the UK, where it is the second commonest cause of cancer death. Despite advances in surgery and adjuvant therapies, 5-year survival remains around 50% [2].


Colorectal Cancer Lynch Syndrome Fecal Occult Blood Testing Flexible Sigmoidoscopy Colonoscopic Surveillance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    WHO. Cancer, fact sheet number 297. Geneva: World Health Organisation, 2009. Accessed 22 Nov 2011
  2. 2.
    Cancer Research UK. By stage at diagnosis. London: Cancer Research UK, 2009. Accessed 22 Nov 2011.
  3. 3.
    Atkin W, Morson B, Cuzik J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Burch JA, Soares-Weiser K, St John DJB, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14:132–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer: a population based, case-controlled study. Ann Intern Med. 2009;150:1–8.PubMedGoogle Scholar
  7. 7.
    Brenner H, Hoffmeister M, Arndt V, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010;102:89–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer using faecal occult-blood test. Lancet. 1996;348:1467–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening and follow up in a prospective randomized study for detection of colorectal cancer by fecal occult-blood testing: results of 68,308 subjects. Scand J Gastroenterol. 1994;29:468–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Mandel JS, Bond JH, Church TR, et al. Reducing mortality by screening for fecal occult blood. N Engl J Med. 1993;328:1365–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Hewitson P, Gasziou P, Irwig L, et al. Cochrane systematic review of colorectal cancer screening using the faecal occult blood test (haemoccult): an update. Am J Gastroenterol. 2008;103:1541–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Atkin WS, Edwards R, Kralj-Hans I, et al. One-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;9276:1624–33.CrossRefGoogle Scholar
  14. 14.
    Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer. 2007;97:1601–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Tappenden P, Chilcott J, Eggington S, et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007;56:677–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Robb KA, Miles A, Wardle J. Demographic and psychosocial factors associated with perceived risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:366–72.PubMedGoogle Scholar
  17. 17.
    Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–89.PubMedCrossRefGoogle Scholar
  18. 18.
    Atkin W, Saunders B. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut. 2002;51(Suppl5):V6–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Vasen HFA, Mšslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57:704–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Boparai KS, Reitsma JB, Lemmens V, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut. 2010;59:1222–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59:975–86.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.The Polyposis RegistrySt Mark’s HospitalMiddlesex, LondonUK

Personalised recommendations